{"url_path":"/sec/apyx/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **         **Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/719135/0001437749-26-018098-index.html","accession_number":"0001437749-26-018098","cik":"0000719135","ticker":"APYX","issuer_name":"Apyx Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/719135/0001437749-26-018098-index.html","primary_entity_key":"0000719135","primary_entity_name":"Apyx Medical Corp"},"word_count":65,"has_tables":true,"body_markdown":"**Item 8.01**         **Other Events**\n\n \n\nOn May 21, 2026, Apyx Medical Corporation issued a press release announcing the publication of a new clinical data in *Aesthetic Surgery Journal Open Forum* highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein."}